Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

91.58 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Mar 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,565
Open 91.58
Bid (Size) 91.85 (34)
Ask (Size) 91.89 (18)
Prev. Close 91.58
Today's Range 91.58 - 91.58
52wk Range 74.09 - 94.26
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What Bear Market? These 2 Winning Stocks Are Still Worth Buying.
These two pharma stocks are rock-solid picks in any kind of market. 
Via The Motley Fool
Why Jounce Therapeutics Shares Are Trading Higher By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 59.6% to $0.2513. Crown Electrokinetics said it has entered into an agreement with a leading infrastructure solutions provider. 
Via Benzinga

Performance

YTD
-0.68%
-0.68%
1 Month
+8.87%
+8.87%
3 Month
-0.02%
-0.02%
6 Month
+19.60%
+19.60%
1 Year
+4.12%
+4.12%

More News

Read More
Elon Musk-Led Neuralink Seeks Human Trial Collaborators, Credit Suisse May Face Disciplinary Action, First Citizens Takeover Silicon Valley Bank: Today's Top Stories
Via Benzinga
FDA Approves Pharming's Immune Disorder Drug, As First APDS Therapy
Via Benzinga
How Is The Market Feeling About Novartis?
Via Benzinga
FDA Approves Novartis' Tafinlar + Mekinist For Pediatric Brain Cancer With Certain Mutations
Via Benzinga
Novartis Surges As It Goes After Eli Lilly's Second Biggest Moneymaker
Via Investor's Business Daily
Why Novartis Shares Are Trading Higher Premarket Today
Via Benzinga
First Republic Bank, KeyCorp And Other Big Stocks Moving Higher In Monday's Pre-Market Session
Via Benzinga
New research project aims to set standardized approach to lipoprotein(a) management
Via NewMediaWire
2 Biotech Stocks That Could Make You Richer
Via The Motley Fool
Two Big Pharma Companies Bow Out Of Neurology Drug Partnerships With Sangamo
Via Benzinga
Novartis Reveals Long-Term Data Of Atrophy Gene Therapy Exhibiting Sustained Durability Of Up To 7.5 Years
Via Benzinga
Elon Musk Frets As Microsoft Axes AI Ethics Team, Richard Branson's Virgin Orbit Stops Ops, Credit Suisse To Borrow Up To $54B: Today's Top Stories
Via Benzinga
Novartis' Prostate Cancer Therapy Hit By Supply Crunch, Seeks To Ramp Up Production To Ease Supply Issues
Via Benzinga
Rise in Biotech Innovations Generating Hope as Pancreatic Cancer Survival Rates Climb
Via FinancialNewsMedia
Exposures Product Safety
3 High Dividend Stocks With Attractive Total Return Potential
Via InvestorPlace
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
Via News Direct
Topics Economy
Exposures Supply Chain
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
Via TheNewswire.com
Topics Economy
Exposures Supply Chain
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
Via Benzinga
4 AI Stocks That Are Revolutionizing Healthcare
Via InvestorPlace
This Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicine's Next Frontier?
Via Benzinga
Week In Review: Keymed/Lepu Sign $1.2 Billion Deal Out-Licensing Claudin 18.2 ADC To AstraZeneca
Via Talk Markets
Novartis Takes Down $80M NASH Pact With Pliant Therapeutics
Via Benzinga
Better Buy: Beam Therapeutics or Intellia Therapeutics?
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.